Gufic Biosciences Limited · NSE:GUFICBIO
Gufic Biosciences — Q1 FY26 Earnings Presentation
35 slides from Gufic Biosciences's earnings presentation, Aug 13, 2025
Slide 1: Stock exchange cover letter for investor presentation
219/LG/SE/AUG/2025/GBSL August 13, 2025 To, To, BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra Kurla Complex, Dalal Street, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 509079 Scrip Symbol: GUFICBIO Subject: Investor Presenta
Slide 2: Delivering Care & Cure - Investor Presentation August 2025
Delivering Care & Cure Investor Presentation August 2025
Slide 3: Safe Harbor
Safe Harbor This presentation has been prepared by and is the sole responsibility of Gufic Biosc iences Lim ited (the “ Company”). By accessing this presentation, you are agreeing to be bound by the trailing restrictions. This presentation does not constitute or form part of any offer or invitation
Slide 4: Q1 FY26 Business & Financial Highlights
Q1 FY26 Business & Financial Highlights
Slide 5: Indore Facility update: From Build to Benchmark
Q1 FY26 Business Highlights Indore Facility update: From Build to Benchmark – Strategic Ramp-Up of Our World-Class Injectable Facility We have built one of the most advanced lyophilized Timeline of our phased approach injectable facilities, commenced production in Milestone Target Status & Commentar
Slide 6: Critical Care Division – Q1 FY26 Highlights
Q1 FY26 Business Highlights Critical Care Division – Q1 FY26 Highlights Strengthening National Presence: Participated in major national conferences (Best of Brussels, W4C, HICCS), engaging 1,500+ consultants across multiple specialties – Intensivists, Infectious Disease Specialists, Nephrologists,
Slide 7: Criticare pipeline and domestic business breakup
Q1 FY26 Business Highlights Criticare’s pipeline of products that address key therapeutic gaps and are complex to manufacture Domestic Business Breakup Drug Class Unique Advantages Complexity in Manufacturing Novel β-lactam/β- Targets multi-drug resistant Gram-negative Complex formulation with dual
Slide 8: Sparsh Division – Q1 FY26
Q1 FY26 Business Highlights Sparsh Division – Q1 FY26: Leadership Transition to Drive Strategic Growth: Appointed Mr. Rajesh Kaul as Division Head — bringing extensive experience from senior roles at Mankind Pharma, Wockhardt, Sun Pharma, Alkem, Aristo, and Zydus Healthcare. Way ahead: Increase
Slide 9: Ferticare Cluster – Q1 FY26
Q1 FY26 Business Highlights Ferticare Cluster – Q1 FY26 Strategic Focus Under New Leadership Performance Highlights Under strengthened leadership and with an Achieved significant growth in overall sales and field productivity on YoY basis upgraded product portfolio, the division’s strategy is Stro
Slide 10: NeuroCare and Aesthaderm – Q1 FY26
Q1 FY26 Business Highlights Botulinum Toxin Segment NeuroCare Division – Q1 FY26: Division Overview Aesthaderm – Q1 FY2025-26 Largest dedicated team for therapeutic Botulinum Toxin (Zarbot) in India, with full Pan-India & Nepal coverage. Expanding Beyond Toxin into a Complete Aesthetics Portfolio FY
Slide 11: Zenova Division – Q1 FY26
Q1 FY26 Business Highlights Zenova Division – Q1 FY26: Strengthening Patient Engagement & Expanding High-Science Portfolio Driving Deeper Patient Engagement Performance & Growth Conducted 394 OPD campaigns in the Gynaecology segment • Achieved 102% of Q1 target, delivering 30% YoY growth. under the
Slide 12: Healthcare Division – Q1 FY26
Q1 FY26 Business Highlights Healthcare Division – Q1 FY26 Product Momentum: Sallaki & Extensions: Continued market leadership in the osteoarthritis Pipeline Driver: and joint care segment, differentiated as not just a pill but a complete Vonoprazan (VonpHa) – Gaining traction as doctors transiti
Slide 13: International Business
Q1 FY26 Business Highlights International Business Strategic Roadmap (3–5 Years) RA Status--> Key Products with Stringent Countries-Ready Dossiers Market Share Goal: Capture 5–10% in identified geographies Regulated Market Current Market Size Portfolio Expansion: Build on current high-value mole
Slide 14: Research & Development
Research & Development Update on R&D Update on Selvax • Peptides R&D: Paving the Way for In-house Critical Developing SVX-3001 (humanized anti-CD40 agonist antibody) co-administered intratumorally with IL-2 to API Manufacturing: Our foray into peptides research amplify anti-tumour immune response wh
Slide 15: Strategic Initiatives
Strategic Initiatives Strategic Initiatives that will further amplify growth over the next few years Increase in overall market and market share in Leverage new biological Botulinum Toxin range of Increase market share in technology platform to products through Commercialization of contract manufact
Slide 16: Profit & Loss Statement
Profit & Loss Statement Particulars Q1 FY26 Q4 FY25 Q1 FY25 FY25 FY24 (in Rs. Crore) Total Revenue 226.9 205 202.8 819.8 806.7 EBITDA 33.2 27 37 140 149.5 EBITDA Margin % 14.63 13.17 18.24 17.35 18.53 Profit before Tax 16.3 10.8 28.1 94.4 115.7 PBT Margins % 7.18 5.27 13.86 11.70 14.34 Tax 4.2 2.8 7
Slide 17: Company Overview
Company Overview
Slide 18: About Gufic Biosciences
About Gufic Biosciences Research based Pharmaceutical Company recognized for its innovative, high quality Pharmaceuticals Nutraceuticals, Natural Herbal products One of the Largest Manufacturers of Lyophilized Injections in India with a wide range of products in various therapy areas BUSINESS STRUCT
Slide 19: World Class Manufacturing Infrastructure
World Class Manufacturing Infrastructure Unit - I at Navsari Unit - II at Navsari Gufic - Belgaum Botulinum Toxin Facility Lyophilized Injectables Facility Natural Products Facility Lyophilized/Powder Injectables Facility Capability to manufacture Liposomal Natural Products (Topical/Liquid) Amphoter
Slide 20: New Manufacturing Infrastructure
New Manufacturing Infrastructure Unit - III at Indore Penem Block UPDATE ON CAPEX Indore Lyophilized/Powder Injectables Dedicated facility for Penem Commercial Production Achieved Facility Carbapenems (Lyophilized / Dry Capability to cater to regulated Powder Inj / Oral Solids / Dual markets such as
Slide 21: Botulinum Toxin Facility
Botulinum Toxin Facility Gufic has built a state-of-the-art manufacturing facility for Botulinum Toxin in Navsari Gufic has partnered with Prime Bio, USA for manufacturing Botulinum Toxin API and formulation Gufic is equipped with all the necessary analytical testing procedures for safety and effica
Slide 22: Consolidating the Domestic Branded Business
Consolidating the Domestic Branded Business Products CRITICAL CARE INFERTILITY MASS SPECIALITY 100+ SKU’s 200+ Field Force: 250 Therapy Areas: Antibacterial, Field Force: >150 Therapy Areas: Hormones, Field Force: >180 Therapy Areas: Anti Infectives, Antifungal, Pain Management, Recombinant Products
Slide 23: Expanding Creditability in CMO Business
Expanding Creditability in CMO Business Offer CMO services for India and 70+ 150+ Products Reliable CMO service for quality products over a Global Markets Companies across multiple therapy areas decade One of the Largest Supplier of Formulations Liposomal Doxycycline Tigecycline Gonadotropins Micafu
Slide 24: Expanding Geographical Reach
Expanding Geographical Reach 130+ Products registered globally (in 15+ countries) 150+ Products in pipeline for registration (in 30+ countries) CANADA | COSTA RICA | PANAMA | COLUMBIA | CHILE | LATVIA | LITHUANIA | BELARUS | GERMANY | AUSTRIA | PORTUGAL | MOROCCO ALGERIA | DOMINICAN REPUBLIC | VENEZ
Slide 25: Building API Capabilities
Building API Capabilities Special Facility dedicated to API Focused on developing non The categories of API’s infringing, novel, cost manufactured are effective and scalable antifungals, antibacterial, chemical process for APIs, anesthetics and Peptides and Cyclopeptides intermediates for antifungal
Slide 26: Strong Partnership & Licensing Deals
Strong Partnership & Licensing Deals Through our collaborations with global partners that are European leader in IV drug researching to expand the frontiers of pharma and delivery systems. Collaborated biotechnology, Gufic will be a technology bridge to the with Gufic to launch Dual future of health
Slide 27: Extensive Sales, Distribution and IT Infrastructure
Extensive Sales, Distribution IT Infrastructure in India 2 Central Warehouses Pan India Presence with a located in North Delhi and field force of 1,000+ West Bhiwandi IT Infrastructure 23 Carrying & Forwarding Retail coverage of more than (C&F) agents across India Integrated IT Systems with Sales 1,
Slide 28: Growth Levers
Growth Levers 1 2 3 INTERNATIONAL INDIA BUSINESS CMO BUSINESS BUSINESS • Consolidation of the Critical Care Infertility • Expand our presence in regulated • Scale up the manufacturing capacity business markets such as US EU • Entry into new therapy areas Dermatology - • Consolidation of the clients
Slide 29: Our Robust R&D and Clinical team to augment growth
Our Robust R&D and Clinical team to augment growth Research & Development (R&D) Clinical Team State-of-the-art R&D Facility in Navsari, Gujarat with expertise in Formulation Development Technology Transfer API Development Patents in various therapy areas Granted: 5 Filed/In-process of filling : 8 Ma
Slide 30: Historical Financials
Historical Financials
Slide 31: Historical Financials
Historical Financials Particulars (Rs. Crs.) FY25 FY24 FY23 FY22 FY21 FY20 FY19 Total Income 823.4 808.8 693.2 782.3 491.4 384.6 359.5 EBITDA 140 149.5 137.2 151.1 87.7 57.9 56.7 EBITDA Margin % 17.00 18.48 19.79 19.31 17.85 15.05 15.77 Profit before Tax 94.4 115.7 106.7 126.8 57.7 30.1 40.2 PBT Mar
Slide 32: Historical Balance Sheet (Equity & Liabilities)
Historical Balance Sheet (Equity & Liabilities) EQUITY & LIABILITIES (Rs. Crs.) Mar-25 Mar-24 Mar-23 Mar-22 Mar-21 Mar-20 Mar-19 Equity Share Capital 10 10 9.7 9.7 9.7 9.7 7.8 Other Equity 591.3 522.5 338.1 259.4 163.7 119.6 67.6 Total Equity 601.3 532.5 347.8 269.1 173.4 129.3 75.4 Non-Current Liab
Slide 33: Historical Balance Sheet (Assets)
Historical Balance Sheet (Assets) ASSETS (Rs. Crs.) Mar-25 Mar-24 Mar-23 Mar-22 Mar-21 Mar-20 Mar-19 Non-Current Assets Property, plant and equipment 475.2 138.3 126.8 105.5 93.8 72.7 70.3 Intangible assets 6.3 5.6 0.7 0.6 0.4 0.6 0.4 Capital work-in-progress 21.8 307.1 169.6 40.9 13.4 30.6 9.6 Righ
Slide 34: Historical Cash Flows
Historical Cash Flows Cash Flow Statement (Rs. Crs.) FY25 FY24 FY23 FY22 FY21 FY20 FY19 Net Profit Before Tax 94.4 115.7 106.7 126.9 57.7 30.1 35.3 Adjustments for: Non - Cash Items / Other Investment 43.8 34.1 29.6 23.2 30.8 24.7 13.4 or Financial Items Operating profit before working capital chang
Slide 35: Thank You
THANK YOU Company: Gufic Biosciences Limited CIN: L24100MH1984PLC033519 Mr. Avik Das – Investor Relations avik.das@guficbio.com Tel: +91 22 67261000